Aptar Awarded U.S. FDA Contract To Study Opportunities For Low Global Warming Potential Propellants For Metered Dose Inhalers; The Contracted Work, Including "Optional Contract Line Items", Is Valued At Up To ~ $6M
Portfolio Pulse from Benzinga Newsdesk
AptarGroup, Inc. (NYSE:ATR) has been awarded a contract by the U.S. FDA to study the development of low Global Warming Potential propellants for metered dose inhalers (MDIs). The contract, including optional items, is valued at up to $6 million. Aptar will leverage its R&D center and respiratory team to provide the FDA with information on formulation, manufacturing, and device design for low-GWP propellant MDIs. The study aims to support FDA's regulatory framework for evaluating and approving these MDIs, with results to be reviewed and potentially published.
December 04, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AptarGroup, Inc. has been awarded a significant contract by the FDA to conduct research on low-GWP propellants for MDIs, which could enhance its position in sustainable healthcare solutions.
The contract with the FDA is likely to have a positive short-term impact on AptarGroup's stock price due to the potential revenue and the strategic importance of the research in the growing field of sustainable healthcare solutions. The contract value of up to $6 million is significant, and the company's involvement in developing environmentally friendly products could improve its market position and investor perception.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100